Curcumin as therapeutics for the treatment of head and neck squamous cell carcinoma by activating SIRT1

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Hu, An ^a   Huang, Jing Juan ^b   Li, Rui Lin ^b   Lu, Zhao Yang ^b   Duan, Jun Li ^b   Xu, Wei Hua ^a   Chen, Xiao Ping ^a   Fan, Jing Ping ^a,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 9; CURCUMIN; SIRT1 PROTEIN, HUMAN; SIRTUIN 1;

ANIMAL; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; HEAD AND NECK NEOPLASMS; HUMAN; METABOLISM; MITOCHONDRION; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CURCUMIN; ENZYME ACTIVATION; HEAD AND NECK NEOPLASMS; HUMANS; MICE, NUDE; MITOCHONDRIA; SIGNAL TRANSDUCTION; SIRTUIN 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940200159     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13429     Document Type: Article

References (45)

1. Hideshima, T., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102, 8567-8572, doi: 10.1073/pnas.0503221102 (2005
2. Catley, L., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-Tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108, 3441-3449, doi: 10.1182/blood-2006-04-016055 (2006
3. Dasmahapatra, G., et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 115, 4478-4487, doi: 10.1182/blood-2009-12-257261 (2010
4. He, L., et al. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discov 3, 324-337, doi: 10.1158/2159-8290.cd-12-0417 (2013
5. Kurundkar, D., et al. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol 266, 233-244, doi: 10.1016/j. taap.2012.11.002 (2013
6. Ohta, M., et al. Positive and negative regulation of podoplanin expression by TGF-beta and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines. Oral Oncol 49, 20-26, doi: 10.1016/j.oraloncology.2012.06.017 (2013
7. Milne, J. C. & Denu, J. M. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol 12, 11-17, doi: 10.1016/j.cbpa.2008.01.019 (2008
8. Sauve, A. A. Pharmaceutical strategies for activating sirtuins. Curr Pharm Des 15, 45-56 (2009
9. Dai, H., et al. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 285, 32695-32703, doi: 10.1074/jbc.M110.133892 (2010
10. Haigis, M. C. & Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5, 253-295, doi: 10.1146/annurev.pathol.4.110807.092250 (2010
11. Lagouge, M., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 127, 1109-1122, doi: 10.1016/j.cell.2006.11.013 (2006
12. Imai, S., Armstrong, C. M., Kaeberlein, M. & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NADdependent histone deacetylase. Nature 403, 795-800, doi: 10.1038/35001622 (2000
13. Borra, M. T., et al. Conserved enzymatic production and biological effect of O-Acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases. J Biol Chem 277, 12632-12641, doi: 10.1074/jbc.M111830200 (2002
14. Jackson, M. D. & Denu, J. M. Structural identification of 2?-And 3?-O-Acetyl-ADP-ribose as novel metabolites derived from the Sir2 family of beta-NAD+-dependent histone/protein deacetylases. J Biol Chem 277, 18535-18544, doi: 10.1074/jbc.M200671200 (2002
15. Yeung, F., et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23, 2369-2380, doi: 10.1038/sj.emboj.7600244 (2004
16. Chua, K. F., et al. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab 2, 67-76, doi: 10.1016/j.cmet.2005.06.007 (2005
17. Firestein, R., et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 3, e2020, doi: 10.1371/journal.pone.0002020 (2008
18. Wang, R. H., et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14, 312-323, doi: 10.1016/j.ccr.2008.09.001 (2008
19. Ford, J., Jiang, M. & Milner, J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65, 10457-10463, doi: 10.1158/0008-5472.can-05-1923 (2005
20. Heltweg, B., et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66, 4368-4377, doi: 10.1158/0008-5472.can-05-3617 (2006
21. Ota, H., et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25, 176-185, doi: 10.1038/sj.onc.1209049 (2006
22. Do, H., et al. A critical re-Assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. Scientific reports 4, 4186, doi: 10.1038/srep04186 (2014
23. Cho, I. R., et al. SIRT1 inhibits proliferation of pancreatic cancer cells expressing pancreatic adenocarcinoma up-regulated factor (PAUF), a novel oncogene, by suppression of beta-catenin. Biochem Biophys Res Commun 423, 270-275, doi: 10.1016/j.bbrc.2012.05.107 (2012
24. Sheshadri, P., et al. Novel Role of Mitochondrial Manganese Superoxide Dismutase in STAT3 Dependent Pluripotency of Mouse Embryonic Stem Cells. Scientific reports 5, 9516, doi: 10.1038/srep09516 (2015
25. Hsieh, Y. W., et al. Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies. Scientific reports 4, 6587, doi: 10.1038/srep06587 (2014
26. Hu, A., et al. Curcumin suppresses invasiveness and vasculogenic mimicry of squamous cell carcinoma of the larynx through the inhibition of JAK-2/STAT-3 signaling pathway. American journal of cancer research 5, 278-288 (2015
27. Chauhan, D., et al. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. British journal of haematology 155, 588-598, doi: 10.1111/j.1365-2141.2011.08888.x (2011
28. Assmus, B., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. The New England journal of medicine 355, 1222-1232, doi: 10.1056/NEJMoa051779 (2006
29. Masuda, T., et al. ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling. Scientific reports 5, 9170, doi: 10.1038/srep09170 (2015
30. Huang, J. J., et al. Angiogenesis effect of therapeutic ultrasound on ischemic hind limb in mice. American journal of translational research 6, 703-713 (2014
31. Duarte, V. M., et al. Curcumin Enhances the Effect of Cisplatin in Suppression of Head and Neck Squamous Cell Carcinoma via Inhibition of IKK beta Protein of the NF kappa B Pathway. Molecular Cancer Therapeutics 9, 2665-2675 (2010
32. Ip, S. W., et al. Induction of apoptotic death by curcumin in human tongue squamous cell carcinoma SCC-4 cells is mediated through endoplasmic reticulum stress and mitochondria-dependent pathways. Cell Biochemistry\s & \sfunction 29, 641-650 (2011
33. Chakravarti, N. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). International Journal of Cancer 119, 1268-1275 (2006
34. Chakravarti, N., et al. Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prevention Research 3, 331-338 (2010
35. Masuelli, L., et al. Resveratrol and diallyl disulfide enhance curcumin-induced sarcoma cell apoptosis. Front Biosci 17, 498-508 (2012
36. Masuelli, L., et al. Resveratrol potentiates the in vitro and in vivo anti-Tumoral effects of curcumin in head and neck carcinomas. Oncotarget 5, 10745-10762 (2014
37. Baur, J. A., Ungvari, Z., Minor, R. K., Le Couteur, D. G. & de Cabo, R. Are sirtuins viable targets for improving healthspan and lifespan? Nature reviews. Drug discovery 11, 443-461, doi: 10.1038/nrd3738 (2012
38. Aggarwal, B. B., Kumar, A. & Bharti, A. C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer research 23, 363-398 (2003
39. Liao, S., et al. Inhibitory effect of curcumin on oral carcinoma CAL27 cells via suppression of Notch1 and NF? B signaling pathways. Journal of Cellular Biochemistry 112, 1055-1065 (2011
40. Aggarwal, B. B. & Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochemical Pharmacology 71, 1397-1421 (2006
41. Yu, Y. C., et al. Radiation-induced senescence in securin-deficient cancer cells promotes cell invasion involving the IL-6/STAT3 and PDGF-BB/PDGFR pathways. Scientific reports 3, 1675, doi: 10.1038/srep01675 (2013
42. Chang, P. Y. Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells. International Journal of Oncology 43, 1141-1150(1110) (2013
43. Vander, B. R., Snow, G. E., Chen, Z. & Van, W. C. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-? B signaling. Oral Oncology 50, 930-941 (2014
44. Hideshima, T., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277, 16639-16647, doi: 10.1074/jbc. M200360200 (2002
45. Zhu, Q., et al. Antinociceptive effects of curcumin in a rat model of postoperative pain. Scientific reports 4, 4932, doi: 10.1038/srep04932 (2014